Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03293992 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03293992 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 27 participants.
The verdict
NCT03293992, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked, placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension including up to two selected doses from Part A and latanoprost 0.005% as active comparator (Part B).
Interventions
- DRUG Matching Placebo
- DRUG Latanoprost 0.005%
- DRUG 0.01% RO7058584
- DRUG 0.1% RO7058584
- DRUG 1% RO7058584
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-10-10 |
| Est. Completion | 2017-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03293992
The ClinicalTrials.gov registry entry for NCT03293992 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Matching Placebo is the first listed.
NCT03293992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03293992 about?
NCT03293992 is a clinical study titled "A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension". This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked, placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension including up to two selected doses from Part A and latanoprost 0.005% as active comparator (Part B).
What is the current status of trial NCT03293992?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2017-10-10. Estimated completion is 2017-12-21.
What interventions are being tested in trial NCT03293992?
The interventions under investigation include: Matching Placebo (DRUG), Latanoprost 0.005% (DRUG), 0.01% RO7058584 (DRUG), 0.1% RO7058584 (DRUG), 1% RO7058584 (DRUG).
Who is sponsoring clinical trial NCT03293992?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.